Open AccessExpression of miR-146a in patients with ovarian cancer and its clinical significance
Author(s) -
Miłosz Wilczyński,
Ewelina Żytko,
Bożena Szymańska,
Monika Dzieniecka,
Marek Nowak,
Justyna Danielska,
Grzegorz Stachowiak,
Jacek R. Wilczyński
Publication year - 2017
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2017.6477
Subject(s) - oncogene , ovarian cancer , serous fluid , molecular medicine , medicine , cancer , malignancy , hazard ratio , oncology , primary tumor , microrna , clinical significance , ovary , pathology , cancer research , biology , cell cycle , metastasis , confidence interval , gene , biochemistry
The aim of the present retrospective study was to compare microRNA (miR)-146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR-146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR-146a was evaluated in formalin-fixed, paraffin-embedded samples. miR-146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR-146a expression in primary tumors and serum levels of cancer antigen 125 (R=-0.37; P=0.03) and Risk of Malignancy Algorithm index (R=-0.79; P=0.0007). Overall survival positively correlated with miR-146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR-146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006). In conclusion, miR-146a may be a prognostic marker for serous ovarian cancer.